Displaying drugs 11251 - 11275 of 11951 in total
Phosphonotyrosine
An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis. [PubChem]
Experimental
Matched Description: … Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly …
WL-1002
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
Matched Description: … WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin …
Indoprofen
A drug that has analgesic and anti-inflammatory properties. Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide.
Withdrawn
Matched Description: … A drug that has analgesic and anti-inflammatory properties. …
PF-232798
PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).
Investigational
Matched Description: … PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple …
Fenpyroximate
Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania).
Investigational
Matched Description: … clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a …
Ladostigil
Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment).
Investigational
Matched Description: … Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety …
Lazertinib
Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer).
Investigational
Matched Description: … Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib …
Veliflapon
Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).
Investigational
Matched Description: … clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a …
Nadecnemab
Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee).
Investigational
Matched Description: … Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and …
Maplirpacept
Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG.
Investigational
Matched Description: … Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory …
BEA-17
BEA-17 is a small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. It is under investigation for the treatment of glioblastoma.
Investigational
Matched Description: … BEA-17 is a small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. …
Licofelone
Developed by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a dual COX/LOX inhibitor and the first member of this new class of analgesic and anti-inflammatory drugs. It is currently under evaluation as a treatment for osteoarthritis (OA), the most common...
Investigational
Matched Description: … Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a ... It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis …
PYM50018
PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in...
Investigational
Matched Description: … PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. ... When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle …
Technetium Tc-99m ciprofloxacin
99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal abscess, pneumonia, appendicitis and tuberculosis. INFECTON combines the widely used antibiotic, ciprofloxacin, with Technetium ((99m)Tc), the most commonly used radioisotope in...
Investigational
Matched Description: … 99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging …
Plozalizumab
Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to...
Investigational
Matched Description: … Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found ... The recruitment of macrophages to the arterial wall is believed to be a critical step in the development …
SYNB1020
SYNB1020 is an engineered strain of Escherichia coli Nissle 1917 developed by Synlogic Inc. It was initially designed to convert ammonia to L-arginine and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016; however, the manufacturer discontinued further development of SYNB1020 to treat...
Investigational
Matched Description: … lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. ... however, the manufacturer discontinued further development of SYNB1020 to treat hyperammonemia due to a …
NGX267
NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
Investigational
Matched Description: … NGX267 is a muscarinic agonist. …
PF-06282999
Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).
Investigational
Matched Description: … Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability …
JNJ-42396302
Jnj 42396302 is under investigation in clinical trial NCT01732237 (A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants).
Investigational
Matched Description: … Jnj 42396302 is under investigation in clinical trial NCT01732237 (A Study to Investigate the Pharmacokinetics …
Reposal
Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.
Experimental
Matched Description: … Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and …
Displaying drugs 11251 - 11275 of 11951 in total